Cairn Biosciences

Cairn Biosciences, founded in 2018, is a private, preclinical-stage biotech based in San Francisco pioneering a new drug discovery paradigm. The company's core asset is the COMPASS platform, which integrates computational modeling, disease biology, and experimental data to simulate cellular dynamics and uncover novel therapeutic interventions. Cairn is leveraging this platform to address the significant unmet need of acquired resistance in oncology, aiming to deliver first-in-class therapeutics. The company is led by an experienced team with a track record in oncology drug discovery and novel technology development.

COMPASS discovery platform: a proprietary system that maps multiscale cell dynamics using computational simulations of living biology to identify novel therapeutic targets and drugs, with an initial focus on overcoming acquired resistance in cancer.

Cairn competes in the crowded computational drug discovery space against other AI/ML-driven biotechs (e.g., Recursion, Insitro, Exscientia) and internal efforts at large pharma. Its differentiation lies in a specific focus on modeling dynamic, adaptive disease biology for oncology resistance, rather than broad compound screening or design.